TWC
BHVN

TD Waterhouse Canada’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

TD Waterhouse Canada’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-420
Closed -$68.5K – 1821
2022
Q3 		$68.5K Hold
420
– – ﹤0.01% 844
2022
Q2 		$64.7K Hold
420
– – ﹤0.01% 883
2022
Q1 		$52.5K Hold
420
– – ﹤0.01% 983
2021
Q4 		$57.1K Buy
+420
New +$53.4K ﹤0.01% 977

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

TD Waterhouse Canada's BHVN Position: Q4 2022 in Review

TD Waterhouse Canada sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 420 shares — an estimated $68.5K sold.

TD Waterhouse Canada first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $68.5K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • TD Waterhouse Canada reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • TD Waterhouse Canada sold 420 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $68.5K.
  • TD Waterhouse Canada first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • TD Waterhouse Canada's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $68.5K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on TD Waterhouse Canada's 13F filing for Q4 2022, filed 13 Nov 2023.